Oak Street Health Announces Participation in Upcoming Investor Conferences

CHICAGO–(BUSINESS WIRE)– Oak Street Health, Inc. (NYSE: OSH, or the “Company”), a network of value-based primary care centers for adults on Medicare, today announced that Mike Pykosz, Chief Executive Officer, and Tim Cook, Chief Financial Officer will participate in the following upcoming investor conferences: The William Blair 42nd Annual Growth Stock Conference, including a presentation at … [Read more…]

Miami Becomes First City in the Nation to Achieve the WELL Health-Safety Rating Across Municipal Building Portfolio

By achieving the WELL rating, Mayor Suarez ensures Miami is “walking the walk” and paving the road for other cities to lead on healthy buildings MIAMI–(BUSINESS WIRE)–The City of Miami, ranked recently as America’s healthiest city, and the International WELL Building Institute (IWBI), the leading authority for transforming health and well-being with its people-first approach … [Read more…]

Elizabeth Goodman Joins Commonwealth Care Alliance® as Chief Legal & Public Affairs Officer

With more than 25 years of experience in health law, policy, programming, and management, Goodman will provide expert counsel to the organization and its board of directors BOSTON–(BUSINESS WIRE)–Commonwealth Care Alliance® (CCA), a national, multi-state healthcare organization with proven expertise in complex care coordination and delivery, today announced the appointment of Elizabeth (Liz) Cahn Goodman, … [Read more…]

Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)

– Marks Kashiv’s second biosimilar approval in 2022 BRIDGEWATER, N.J.–(BUSINESS WIRE)–Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA®. FYLNETRA was developed … [Read more…]

OneCellDx and Genetics Institute of America Partner to Launch OncoPredikt HRD Assay

Ideal for HRD Screening Pharma Development AI Enabled Algorithm Poster Session at ASCO 2022 CUPERTINO, CA & DELRAY BEACH, Fla.–(BUSINESS WIRE)–#CAPaccredited–OneCellDx and Genetics Institute of America announced today that they have signed a memorandum of understanding for a diagnostics commercialization agreement for the OneCellDx OncoPredikt HRD Assay. Genetics Institute of America will create a laboratory … [Read more…]

BIOTECanada Announces Addition of Directors to Board of Directors

TORONTO–(BUSINESS WIRE)–Following the Annual General Meeting of BIOTECanada, the Board of Directors is announcing the election of three additional Directors to the Board. The new Directors include: Colleen Coxson, Country Manager, Alnylam Pharmaceuticals Rhonda Pacheco, President and General Manager, Eli Lilly Canada Nancy Pei, Partner, Smart & Biggar “On behalf of the BIOTECanada team and … [Read more…]

BetterHelp and REFORM Alliance Provide Free Therapy to Formerly Incarcerated Individuals

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–BetterHelp, the world’s largest therapy service, partners with REFORM Alliance, in their latest social impact partnership to provide free therapy to people impacted by the criminal justice system. REFORM Alliance aims to transform probation and parole by changing laws, systems, and culture to create real pathways to work and wellbeing. They’re working … [Read more…]

Worldwide Lignocaine Industry to 2027 – Rising Chronic and Acute Pain is Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Lignocaine Market 2021-2027” report has been added to ResearchAndMarkets.com’s offering. The global lignocaine market is anticipated to grow at a considerable CAGR during the forecast period. The increase in the number of surgical operations including dental procedures, aesthetic surgery, and plastic surgeries across the globe has created demand for lignocaine to alleviate … [Read more…]

Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022. Jefferies 2022 Global Healthcare Conference (in … [Read more…]